Immediate and early percutaneous coronary intervention in very high-risk and high-risk non-ST segment elevation myocardial infarction patients

Lior Lupu MD, MBA1 | Louay Taha MD2 | Ariel Banai MD1
Hezzy Shmueli MD3 | Ariel Borohovitz MD1 | Shlomi Matetzky MD4
Mustafa Gabarin MD5 | Mony Shuvy MD2 | Roy Beigel MD4
Katia Orvin MD6 | Sa'ar Minha MD7 | Yacov Shacham MD1
Shmuel Banai MD1 | Michael Glikson MD2 | Elad Asher MD, MHA2

1Department of Cardiology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
2Department of Cardiology, Jesselson Integrated Heart Center, Shaare Zedek Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel
3Department of Cardiology, Soroka Medical Center, Beer-Sheva, Israel and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
4Department of Cardiology, Sheba Medical Center, Ramat Gan, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
5Department of Cardiology, Meir Medical Center, Kfar Saba, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
6Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
7Department of Cardiology, Shamir Medical Center, Be’er Ya’akov, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Correspondence
Lior Lupu, MD, MBA, Department of Cardiology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Email: lupul@tlvmc.gov.il

Abstract

Background: The European Society of Cardiology (ESC) guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (non-ST-segment elevation myocardial infarction [NSTEMI]) has recommended immediate (<2 h) percutaneous coronary intervention (PCI) in very-high risk patients and early (<24 h) PCI in high-risk patients.

Hypothesis: To examine the ESC NSTEMI guidelines adherence in a nationwide survey in Israel using the Acute Coronary Syndrome Israeli Survey (ACSIS). We hypothesized that adherence to the guidelines’ recommended PCI timing in NSTEMI patients will be inadequate, partly due to the inconsistent evidence regarding its effect on clinical outcomes.

Methods: All NSTEMI patients who underwent PCI during the ACSIS surveys in 2016 and 2018 were included in the analysis.

Results: Out of 1793 NSTEMI patients, 1643 (92%) patients underwent PCI, and door to balloon time was documented in 1078 of them. One hundred and fifty-six (14.5%) patients and 922 (85.5%) patients were defined as very high-risk and high-risk NSTEMI patients, respectively. Early coronary angiography was performed in 405 (43.9%) patients. Patients in whom coronary angiography was postponed were older and had more comorbidities.

Conclusions: Despite guidelines recommendations for immediate and early PCI in very high-risk and high-risk NSTEMI patients, respectively, most patients do not...
Acute coronary syndrome (ACS) is the acute form of ischemic heart disease, which is the leading cause of death globally. This definition of ACS ranges from ST-segment elevation myocardial infarction (STEMI) to non-STEMI (NSTEMI) and unstable angina (UA). Immediate primary percutaneous intervention (PCI) is the gold standard for the treatment of STEMI. By contrast, routine use of coronary angiography, and its timing, in NSTEMI patients is still debatable. Several meta-analyses support the role of a routine early (<24 h) PCI in reducing the risk of composite ischemic outcomes, particularly in high-risk patients. Moreover, randomized controlled trials have shown that very high-risk and high-risk NSTEMI patients may benefit from an early invasive strategy. Accordingly, the last two European Society of Cardiology (ESC) guidelines (2015, 2020) for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTEMI) recommend an immediate and early routine PCI in very high-risk and high-risk NSTEMI patients, respectively. We aim to examine adherence to these recommendations in a nationwide survey.

2 METHODS

Patients were derived from the ACS Israeli Survey (ACSIS). Details about this registry have been previously reported. In brief, the ACSIS is a nationwide survey conducted during March and April of 2016 and 2018 in all 25 cardiac units and cardiology wards operating in Israel. Local ethics committee approval was received from each hospital. Participants provided their written informed consent to participate in the study. The study population comprised all patients admitted with ACS.

Prespecified forms were used to collect demographic and clinical data. The discharge diagnoses were determined by the attending physician based on clinical, electrocardiogram, and biochemical tests. Patients’ treatment was determined by the decision of the attending physician.

2.1 Study population

The study population consisted of patients included in the ACSIS surveys in 2016 and 2018 with the diagnosis of NSTEMI, which was defined according to contemporary guidelines. Patients were considered to have NSTEMI if they had acute chest discomfort with no persistent ST-segment elevation and elevated troponin. The ECG findings ranged from normal ECG to changes that may include transient ST-segment elevation, persistent or transient ST-segment depression, T-wave inversion, flat T waves, or pseudonormalization of T waves. Patients’ risk stratification was performed according to the 2015 ESC guidelines. Very high-risk patients were defined when they had one or more of the following: hemodynamic instability or cardiogenic shock; ongoing or recurrent pain refractory to medical treatment; life-threatening arrhythmias or cardiac arrest; mechanical complications; or an acute heart failure. High-risk patients were defined by one or more of the following: rise or fall in troponin compatible with myocardial infarction (MI); dynamic ST-segment or T-wave changes; or GRACE score higher than 140. The investigators who determined the risk category were blinded to clinical outcomes. Time to coronary angiography was divided into three categories: immediate coronary angiography was done <2 h from admission; early coronary angiography was done <24 h from admission; and late coronary angiography was done >24 h from admission. We defined 30-days major cardiovascular adverse events (MACE) as the occurrence in 30 days of either: mortality, UA pectoris, MI, stent thrombosis, urgent revascularization, and cerebrovascular event.

2.2 Statistical analysis

Patients’ characteristics were presented as numbers (%) for categorical variables and as means (SD) or medians (IQR) for normal and nonnormal distributed continuous variables, respectively.

A χ² test for trends was used for the comparison of categorical variables. Analysis of variance with 1 degree of freedom was performed for comparison of normally distributed continuous variables and Kendall rank correlation for nonnormal distribution.

For MACE and 1-year mortality outcomes, univariable and multivariable logistic regressions were performed with prespecified covariates. All covariates have less than 5% missing data except for family history of coronary artery disease, which was not included in the multivariable model.

An interaction term (PCI time × Risk class) was assessed, unadjusted for other covariates. Models were assessed among high-risk and very high-risk patients separately.
All tests were conducted at a two-sided overall 5% significance level ($\alpha = .05$).

All analyses were performed using R software (R Development Core Team, version 4.0.3).

3 | RESULTS

A total of 1793 patients were diagnosed with NSTEMI during the study period. Coronary angiography was performed in 1643 (92%) patients. Time to intervention was documented in 1078 patients. Of them, 156 (14.5%) and 922 (85.5%) patients were defined as very high-risk and high-risk NSTEMI patients, respectively. Acute heart failure was the main reason (89.1%) for including patients in the very high-risk NSTEMI category (Table S1).

3.1 | Intergroup analyses

Patients in the very high-risk group were older and with a higher proportion of women as compared with the high-risk group. Furthermore, these patients had more comorbidities, including hypertension, hyperlipidemia, active smoking status, diabetes mellitus, family history of ischemic heart disease, history of chronic kidney disease, peripheral vascular disease, cerebrovascular disease, history of MI, PCI, coronary artery bypass grafting (CABG), congestive heart failure (CHF), and a higher proportion of GRACE score > 140 (Table 1).

3.1.1 | Outcomes

No difference was found in the PCI rate during the index hospitalization between the groups. However, patients in the very high-risk group had a higher number of diseased vessels and had a higher proportion of left main (15.5% vs. 3.3%, respectively; $p < .001$) and left anterior descending (LAD) (61.2% vs. 48.9%, respectively; $p = .029$) arteries PCI. Moreover, patients in the very high-risk group had lower ejection fractions (EFs) (Table 2).

MACE occurred more frequently in the very high-risk group (20.1% and 5.8%, respectively; $p < .001$), with higher rates of recurrent MIs (8.1% vs. 0.6%, respectively; $p < .001$) and 30-days mortality (9.1% vs. 0.4%, respectively; $p < .001$). One-year mortality was also significantly higher in the very-high-risk group (23.3% vs. 3.1%, respectively; $p < .001$).

In a multivariate analysis of the full patient cohort, the very high-risk category was associated with 1-year mortality (OR: 7.7, 95% CI: 4.3–13.9; $p < .001$). Age and a history of MI were also significantly

### TABLE 1 Baseline patients’ characteristics

|                                | Very high risk | High risk | $p$ value |
|--------------------------------|----------------|-----------|-----------|
| **n**                          | 156            | 922       |           |
| **Baseline characteristics**   |                |           |           |
| Age, years (median [IQR])      | 68.50 (64.00, 77.00) | 65.00 (56.00, 73.00) | <.001     |
| Gender (male)                  | 106 (67.9)     | 741 (80.4)| .001      |
| Dyslipidemia                   | 119 (76.8)     | 708 (76.8)| 1         |
| Hypertension                   | 134 (86.5)     | 625 (67.8)| <.001     |
| Current smokers                | 43 (27.6)      | 355 (38.5)| .011      |
| Diabetes mellitus              | 95 (60.9)      | 394 (42.8)| <.001     |
| Family history of CAD          | 26 (21.5)      | 254 (34.1)| .008      |
| BMI (kg/m²), (median [IQR])    | 27.26 (24.67, 31.59) | 27.46 (24.61, 30.25) | .771      |
| Prior MI                       | 84 (54.5)      | 379 (41.2)| .003      |
| Prior CABG                     | 25 (16.1)      | 97 (10.5)| .057      |
| Prior PCI                      | 72 (47.1)      | 331 (36.0)| .012      |
| Chronic renal failure          | 45 (29.0)      | 87 (9.4)| <.001     |
| Peripheral vascular disease    | 23 (14.8)      | 55 (6.0)| <.001     |
| Cerebrovascular disease        | 30 (19.2)      | 74 (8.0)| <.001     |
| CHF                            | 37 (23.9)      | 66 (7.2)| <.001     |
| GRACE score > 140              | 52 (36.4)      | 120 (13.5)| <.001     |

Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention.
associated with a 1-year mortality rate. However, late PCI (>24 h) was not associated with a higher 1-year mortality rate (0.96, 95% CI: 0.5–1.8; p = .89) (Table S2). In a univariate analysis, a very high-risk category was significantly associated with 30-days MACE (OR: 4.06, 95% CI: 2.49–6.53; p < .001) (Table S3).

3.2 | Intragroup analyses

### Very high-risk group

Out of the 156 patients in the very high-risk group, only 10 patients (6.4%) underwent immediate coronary angiography, and only 50 (32.1%) patients underwent early coronary angiography. The majority 96 (61.5%) of patients had their PCI performed after more than 24 h (Figure 1A). Overall, the median time to PCI was 35.12 h (IQR: 15.3–71.12) in the very high-risk NSTEMI group. Baseline characteristics were similar between subgroups (Table 3a). GRACE score ≥140 was documented in 6 (75%), 18 (39.1%), and 28 (31.5) of the immediate, early, and late PCI groups, respectively. Patients in the immediate and early coronary angiography subgroups had more ventricular arrhythmias as compared with the late angiography group (4 [11%], 1 [8%], and 0, respectively; p < .04). Cardiogenic shock was more common in the immediate and early PCI groups as compared with the late PCI group (4 [40%], 7 [14%], and 3 [3.1%], respectively; p < .001).

### Clinical outcomes in all cohort

|                  | Very high risk | High risk | p value |
|------------------|----------------|-----------|---------|
| n (%)            | 156            | 922       |         |
| **Reperfusion therapy** |                 |           |         |
| PCI               | 103 (66.0)     | 615 (66.7)| .941    |
| Angiography       | 156 (100.0)    | 922 (100.0)| NA      |
| **Number of diseased vessels** |             |           | <.001   |
| None              | 16 (15.5)      | 20 (3.3)  | <.001   |
| 1 vessel          | 63 (61.2)      | 301 (48.9)| 0.029   |
| 2 vessels         | 33 (32.0)      | 315 (35.0)| 0.642   |
| 3 vessels         | 29 (50.0)      | 288 (31.4)| .636    |
| PCI to LM         | 16 (15.5)      | 20 (3.3)  | <.001   |
| PCI to LAD        | 63 (61.2)      | 301 (48.9)| 0.029   |
| PCI to LCX        | 33 (32.0)      | 215 (35.0)| 0.642   |
| PCI to RCA        | 30 (29.1)      | 197 (32.0)| 0.636   |
| PCI to SVG        | 4 (4.1)        | 17 (3.0)  | .781    |
| PCI to arterial graft | 0 (0.0) | 2 (0.4)   | 1       |
| **EF classes**    |                |           | <.001   |
| Normal (EF > 50%) | 59 (41.8)      | 513 (66.9)|         |
| Mild (EF: 40%-50%)| 29 (20.6)      | 178 (23.2)|         |
| Moderate (EF: 30%-40%)| 32 (22.7) | 61 (8.0)  |         |
| Severe (EF < 30%) | 21 (14.9)      | 15 (2.0)  |         |
| **30-day clinical outcomes** |            |           |         |
| Rehospitalization| 19 (14.4)      | 141 (16.8)| .563    |
| Recurrent MI      | 12 (8.1)       | 5 (0.6)   | <.001   |
| Recurrent angina  | 1 (1.4)        | 16 (3.2)  | .635    |
| MACE<sup>a</sup>  | 31 (20.1)      | 53 (5.8)  | <.001   |
| **Death rates**   |                |           |         |
| 30-day mortality  | 14 (9.1)       | 4 (0.4)   | <.001   |
| 1-year mortality  | 34 (23.3)      | 26 (3.1)  | <.001   |
| Overall mortality | 39 (25.0)      | 42 (4.6)  | <.001   |

**Abbreviations:** EF, ejection fraction; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention; RCA, right coronary artery; SVG, Saphenous vein graft.

<sup>a</sup>MACE was defined as 30-days mortality, recurrent myocardial infarction, unstable angina, urgent revascularization, stent thrombosis, and cerebrovascular event.
### TABLE 3a Patients' characteristics in the very high-risk group

|                      | Immediate PCI | Early PCI | Late PCI | \( p_{\text{trend}} \) |
|----------------------|---------------|-----------|----------|------------------------|
| **Baseline characteristics** |               |           |          |                        |
| Age, years (median [IQR]) | 67.00 (61.00, 72.25) | 71.00 (66.00, 80.00) | 68.00 (63.00, 77.00) | .763 |
| Gender (male)          | 8 (80.0)      | 38 (76.0) | 60 (62.5) | .072 |
| Dyslipidemia           | 8 (80.0)      | 39 (78.0) | 72 (75.8) | .697 |
| Hypertension           | 9 (90.0)      | 42 (84.0) | 83 (87.4) | .844 |
| Current smokers        | 2 (20.0)      | 13 (26.0) | 28 (29.2) | .502 |
| Diabetes mellitus      | 8 (80.0)      | 25 (50.0) | 62 (64.6) | .663 |
| Family history of CAD  | 3 (37.5)      | 5 (13.5)  | 18 (23.7) | .889 |
| BMI (kg/m\(^2\)), (median [IQR]) | 25.11 (21.59, 25.25) | 27.76 (25.53, 31.25) | 26.97 (24.62, 31.83) | .801 |
| Prior MI               | 7 (70.0)      | 24 (48.0) | 53 (56.4) | .962 |
| Prior CABG             | 3 (30.0)      | 9 (18.0)  | 13 (13.7) | .844 |
| Prior PCI              | 5 (50.0)      | 15 (30.0) | 52 (55.9) | .037 |
| Chronic renal failure  | 2 (20.0)      | 15 (30.0) | 28 (29.5) | .703 |
| Peripheral vascular disease | 1 (10.0) | 7 (14.0) | 15 (15.8) | .61 |
| Cerebrovascular disease| 2 (20.0)      | 9 (18.0)  | 19 (19.8) | .878 |
| CHF                   | 4 (40.0)      | 9 (18.0)  | 24 (25.3) | .929 |
| GRACE score > 140      | 6 (75.0)      | 18 (39.1) | 28 (31.5) | .03 |
| **Prior medications**  |               |           |          |                        |
| Aspirin               | 6 (60.0)      | 27 (60.0) | 60 (69.8) | .271 |
| Clopidogrel           | 2 (25.0)      | 6 (15.0)  | 20 (26.0) | .373 |
| ACE inhibitors        | 4 (50.0)      | 12 (32.4) | 35 (48.6) | .351 |
| ARB                   | 1 (20.0)      | 7 (21.2)  | 19 (30.2) | .338 |
| Beta-blockers         | 5 (55.6)      | 24 (60.0) | 54 (64.3) | .524 |
| Statins               | 7 (77.8)      | 24 (75.0) | 60 (81.1) | .571 |
| Calcium channel blockers | 4 (66.7) | 14 (42.4) | 31 (42.5) | .455 |
| Nitrates              | 1 (20.0)      | 1 (3.1)   | 8 (12.1)  | .538 |
| Diuretics             | 2 (28.6)      | 7 (20.0)  | 35 (46.1) | .021 |
| **Vital signs on FMC** |               |           |          |                        |
| Admission Killip class |             |           |          |                        |
| I                     | 2 (22.2)      | 24 (48.0) | 35 (37.2) | .808 |
| II                    | 3 (33.3)      | 16 (32.0) | 39 (41.5) | .297 |
| III                   | 2 (22.2)      | 10 (20.0) | 18 (19.1) | .822 |
| IV                    | 2 (22.2)      | 0 (0.0)   | 2 (2.1)   | .062 |
| Heart rate (bpm) (median [IQR]) | 92.00 (72.00, 107.00) | 82.00 (71.00, 103.00) | 90.00 (78.00, 106.25) | .207 |
| Systolic blood pressure (mmHg) (median [IQR]) | 137.00 (117.00, 152.00) | 139.00 (120.00, 160.00) | 153.00 (128.50, 169.00) | .046 |
| Diastolic blood pressure (mmHg) (median [IQR]) | 75.00 (65.00, 87.00) | 80.00 (71.00, 90.00) | 85.00 (72.50, 97.00) | .038 |
| Atrial fibrillation-supraventricular tachycardia | 0 (0.0) | 3 (6.0) | 10 (10.4) | .18 |
| VT/VF                 | 1 (10.0)      | 4 (8.0)   | 0 (0.0)   | .005 |
| 2nd to 3rd degree AV block | 0 (0.0) | 0 (0.0) | 1 (1.0) | .463 |

(Continues)
| TABLE 3a (Continued) | Immediate PCI | Early PCI | Late PCI | p_trend |
|----------------------|---------------|-----------|----------|---------|
| **Reperfusion therapy** |               |           |          |         |
| PCI                  | 7 (70.0)      | 34 (68.0) | 62 (64.6) | .623    |
| Coronary angiography | 10 (100.0)    | 50 (100.0) | 96 (100.0) | NaN     |
| **In-hospital complications** |           |           |          |         |
| Mild-moderate CHF (Killip-2) | 2 (22.2) | 17 (34.0) | 29 (30.2) | .987    |
| Pulmonary edema (Killip-3) | 1 (11.1) | 9 (18.0) | 25 (26.0) | .165    |
| Cardiogenic shock (Killip-4) | 4 (40.0) | 7 (14.0) | 3 (3.1) | <.001   |
| Hemodynamically significant right ventricle infarction | 0 (0.0) | 1 (2.0) | 0 (0.0) | .367    |
| Recurrent MI          | 0 (0.0)       | 4 (8.0)   | 7 (7.3)  | .633    |
| Recurrent angina/ischemia | 1 (10.0) | 1 (2.0) | 3 (3.1) | .566    |
| Stent thrombosis      | 0 (0.0)       | 0 (0.0)   | 0 (0.0)  | NaN     |
| Free wall rupture     | 0 (0.0)       | 0 (0.0)   | 1 (1.0)  | .463    |
| Tamponade             | 0 (0.0)       | 0 (0.0)   | 1 (1.0)  | .463    |
| Moderate to severe mitral regurgitation | 1 (10.0) | 5 (10.0) | 7 (7.3) | .581    |
| Pericarditis          | 0 (0.0)       | 1 (2.0)   | 0 (0.0)  | .367    |
| Sustained VT (>125 bpm) | 1 (10.0) | 3 (6.0) | 3 (3.1) | .241    |
| Primary VF            | 0 (0.0)       | 0 (0.0)   | 1 (1.0)  | .463    |
| Secondary VF          | 0 (0.0)       | 1 (2.0)   | 1 (1.0)  | .905    |
| New atrial fibrillation | 0 (0.0) | 8 (16.0) | 7 (7.3) | .574    |
| High degree (2nd to 3rd) AV block | 0 (0.0) | 1 (2.0) | 0 (0.0) | .367    |
| Asystole              | 0 (0.0)       | 3 (6.0)   | 3 (3.1)  | .834    |
| Stroke                | 1 (10.0)      | 0 (0.0)   | 0 (0.0)  | .011    |
| Acute renal failure   | 2 (20.0)      | 10 (20.4) | 15 (15.6) | .494    |
| Bleeding              | 0 (0.0)       | 2 (4.0)   | 4 (4.2)  | .638    |
| Blood transfusions    | 0 (0.0)       | 3 (6.0)   | 5 (5.2)  | .727    |
| **Laboratory tests**  |               |           |          |         |
| Peak CK (U/L) value (median [IQR]) | 670.00 (409.00, 1400.00) | 545.00 (305.50, 1328.00) | 210.00 (116.00, 475.50) | <.001 |
| Peak troponin I elevated | 4 (100.0) | 17 (85.0) | 30 (85.7) | .625    |
| Peak troponin T elevated | 6 (100.0) | 32 (94.1) | 63 (98.4) | .512    |
| Earliest creatinine (mg/dl) (median [IQR]) | 1.33 (0.94, 1.80) | 1.19 (0.94, 1.51) | 1.10 (0.87, 1.46) | .178    |
| **Treatment at discharge** |           |           |          |         |
| Aspirin               | 8 (100.0)     | 43 (97.7) | 88 (96.7) | .564    |
| P2Y12                 | 8 (100.0)     | 40 (93.0) | 80 (87.9) | .184    |
| P2Y12 type            |               |           |          |         |
| Prasugrel             | 2 (20.0)      | 5 (11.1)  | 8 (9.0)  | .328    |
| Ticagrelor            | 5 (50.0)      | 25 (55.6) | 33 (37.1) | .076    |
| Clopidogrel           | 3 (30.0)      | 15 (33.3) | 48 (53.9) | .018    |
| Statins               | 8 (100.0)     | 44 (97.8) | 90 (98.9) | .855    |
| ACE-I/ARB             | 7 (100.0)     | 38 (92.7) | 62 (81.6) | .048    |
| Beta-blockers         | 7 (87.5)      | 38 (88.4) | 72 (86.7) | .835    |
3.2.2 | Outcomes

MACE occurred in 3 patients (30%) in the immediate group, 14 patients (28%) in the early group, and 14 patients (14.9%) in the late group, ($p = .053$). Mortality rates at 30‐day were 20%, 14%, and 5.3%, respectively ($p = .034$). Mortality rates at 1‐year were 20%, 25%, and 22.7%, respectively ($p = .959$). There was a trend for more recurrent hospitalization in the immediate and early intervention groups as compared with the late intervention group (2 [25%] and 9 [22%] vs. 8 [9.6%], respectively; $p = .05$) (Table 3a).

In a univariate analysis of the very high‐risk patients, late PCI was associated with reduced risk for 30‐days MACE (OR: 0.44; 95% CI: 0.2, 0.98, $p = .045$) (Table S3). This association is not seen when adjusting for the other risk factors (Table S4).

### Table 3a (Continued)

|                      | Immediate PCI | Early PCI | Late PCI | $p_{\text{trend}}$ |
|----------------------|---------------|-----------|----------|-------------------|
| **30‐day clinical outcomes** |               |           |          |                   |
| Rehospitalization    | 2 (25.0)      | 9 (22.0)  | 8 (9.6)  | .05               |
| Recurrent MI         | 0 (0.0)       | 4 (8.3)   | 8 (8.9)  | .462              |
| Recurrent angina     | 0 (0.0)       | 0 (0.0)   | 1 (2.1)  | .503              |
| MACE$^*$             | 3 (30.0)      | 14 (28.0) | 14 (14.9)| .053              |
| **Death rates**      |               |           |          |                   |
| 30‐day mortality     | 2 (20.0)      | 7 (14.0)  | 5 (5.3)  | .034              |
| 1‐year mortality     | 2 (20.0)      | 12 (25.0) | 20 (22.7)| .959              |

Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; AV, atrioventricular; BMI, Body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; VF, ventricular fibrillation; VT, ventricular tachycardia.

$^*$MACE was defined as 30‐days mortality, recurrent myocardial infarction, unstable angina, urgent revascularization, stent thrombosis, and cerebrovascular event.

### 3.2.3 | High‐risk group

In the high‐risk group, 33 (3.6%) patients underwent immediate PCI, 372 (40.3%) patients underwent early PCI, and the rest 517 (56.1%) underwent late PCI (Figure 1B). The median time to PCI was 27 h (IQR: 16.6–56.3). Compared with the immediate and early PCI groups, patients in the late PCI subgroup were older (Table 3b).

Furthermore, hypertension, dyslipidemia, diabetes, chronic kidney disease, tobacco use, and a family history of ischemic heart disease were more common in the late PCI group. These patients had higher rates of prior MI, PCI, and CABG. Accordingly, these patients were more often chronically treated with antithrombotic, antihypertensive, heart failure, and anti‐ischemic medication. Patients in the late intervention group were less likely to require intervention during coronary angiography (331 [64%] in the late intervention group vs. 25 [75.8%] in the immediate intervention group, and 259 [69.6%] in the early intervention group; $p = .038$). Patients in the late intervention group were more commonly discharged with clopidogrel as compared with patients in the immediate PCI group who were treated more often with prasugrel.

### 3.2.4 | Outcome

No difference in MACE rate, mortality, or rehospitalization rate was found between the different intervention groups.

In univariate and multivariate logistic regression models, late PCI was not associated with a higher risk for 30‐days MACE (Tables S3 and S4).

### 4 | DISCUSSION

In this nationwide survey, among NSTEMI patients classified as very high‐risk, only 6.4% underwent immediate PCI according to contemporary guidelines, while the majority of them (61.5%) underwent late PCI. Moreover, among patients with high‐risk NSTEMI, only 43.9% underwent immediate or early PCI, while 56.1% of patients underwent late PCI. Our findings unequivocally demonstrate a large gap between the guidelines’ recommendation and the daily practice treatment in a nationwide survey.

There are several explanations for these findings. First is the lack of consistent evidence for improved outcomes in immediate and early intervention. Very high‐risk patients have generally been excluded from randomized controlled trials; hence, the recommendation for immediate PCI (class IC) is largely based on the fact that these patients have a poor prognosis with conservative treatment. Among the high‐risk group, there are a number of randomized controlled trials addressing the issue; however, the data are inconclusive. One of the reasons is the heterogeneity of these studies. Importantly, the actual time to intervention in the early intervention group varies widely between the studies. For example, the studies on which the
| Basis for PCI         | Immediate PCI | Early PCI | Late PCI | p_trend |
|----------------------|---------------|-----------|----------|---------|
| Age, years (median [IQR]) | 61.00 (52.00, 72.00) | 62.00 (54.00, 71.00) | 66.00 (58.00, 74.00) | <.001   |
| Gender (male)        | 29 (87.9)     | 306 (82.3) | 406 (78.5) | .079    |
| Dyslipidemia         | 25 (75.8)     | 272 (73.1) | 411 (79.5) | .048    |
| Hypertension         | 16 (48.5)     | 233 (62.6) | 376 (72.7) | <.001   |
| Current smokers      | 18 (54.5)     | 154 (41.4) | 183 (35.4) | .011    |
| Diabetes mellitus    | 8 (24.2)      | 141 (38.1) | 245 (47.4) | <.001   |
| Family history of CAD| 13 (44.8)     | 117 (36.9) | 124 (31.1) | .041    |
| BMI (kg/m²), (median [IQR]) | 26.42 (22.93, 28.48) | 27.47 (24.54, 30.09) | 27.47 (24.75, 30.53) | .214    |
| Prior MI             | 10 (30.3)     | 133 (35.8) | 236 (45.8) | .001    |
| Prior CABG           | 3 (9.1)       | 25 (6.7)   | 69 (13.3)  | .004    |
| Prior PCI            | 9 (27.3)      | 112 (30.1) | 210 (40.9) | .001    |
| Chronic renal failure| 1 (3.0)       | 22 (5.9)   | 64 (12.4)  | .001    |
| Peripheral vascular disease | 1 (3.0) | 18 (4.8) | 36 (7.0) | .133    |
| Cerebrovascular disease | 1 (3.0) | 26 (7.0) | 47 (9.1) | .126    |
| CHF                  | 2 (6.1)       | 19 (5.1)   | 45 (8.7)   | .06     |
| GRACE score > 140    | 6 (19.4)      | 37 (10.4)  | 77 (15.4)  | .193    |

Prior medications

| Medication               | Immediate PCI | Early PCI | Late PCI | p_trend |
|--------------------------|---------------|-----------|----------|---------|
| Aspirin                  | 12 (38.7)     | 154 (45.2)| 274 (59.3)| <.001   |
| Clopidogrel              | 3 (10.0)      | 40 (12.5) | 74 (17.1) | .058    |
| ACE inhibitors           | 6 (21.4)      | 95 (31.6) | 158 (39.5)| .007    |
| ARB                      | 6 (23.1)      | 56 (21.4) | 95 (26.4) | .197    |
| Beta-blockers            | 15 (53.6)     | 114 (37.6)| 232 (53.6)| .001    |
| Statins                  | 14 (63.6)     | 175 (66.8)| 292 (78.9)| .001    |
| Calcium channel blockers | 4 (14.8)      | 53 (20.2) | 131 (35.6)| <.001   |
| Nitrates                 | 1 (3.8)       | 10 (4.1)  | 29 (8.7)  | .03     |
| Diuretics                | 5 (20.0)      | 27 (10.5) | 79 (22.1) | .003    |

Vital signs on FMC

| Vital sign               | Immediate PCI | Early PCI | Late PCI | p_trend |
|--------------------------|---------------|-----------|----------|---------|
| Admission Killip class   |               |           |          | NaN     |
| I                        | 32 (100.0)    | 356 (100.0)| 492 (100.0)| NaN |
| II-V                     | 0 (0.0)       | 0 (0.0)   | 0 (0.0)  | NaN    |
| Heart rate (bpm) (median [IQR]) | 81.50 (72.00, 90.00) | 76.00 (66.00, 86.00) | 78.00 (68.00, 88.00) | .343 |
| Systolic blood pressure (mmHg) (median [IQR]) | 142.00 (121.00, 150.00) | 147.00 (131.00, 160.00) | 147.00 (130.00, 161.00) | .603 |
| Diastolic blood pressure (mmHg) (median [IQR]) | 83.50 (70.75, 98.00) | 83.00 (74.00, 93.00) | 81.00 (71.00, 91.00) | .083 |
| Atrial fibrillation/supraventricular tachycardia | 1 (3.0) | 12 (3.2) | 27 (5.2) | .153 |
| VT/VF                    | 0 (0.0)       | 0 (0.0)   | 0 (0.0)  | NaN    |
| 2nd to 3rd degree AV block | 0 (0.0) | 1 (0.3)  | 2 (0.4)  | .664   |

Reperfusion therapy

| Therapy               | Immediate PCI | Early PCI | Late PCI | p_trend |
|-----------------------|---------------|-----------|----------|---------|
| PCI                   | 25 (75.8)     | 259 (69.6)| 331 (64.0)| .038    |
| Coronary angiography | 33 (100.0)    | 372 (100.0)| 517 (100.0)| NaN    |
**Table 3b (Continued)**

| In-hospital complications | Immediate PCI | Early PCI | Late PCI | p_trend |
|---------------------------|---------------|-----------|---------|---------|
| In-hospital complications |               |           |         |         |
| Mild-moderate CHF (Killip-2) | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Pulmonary edema (Killip-3) | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Cardiogenic shock (Killip-4) | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Hemodynamically significant right ventricle infarction | 0 (0.0) | 0 (0.0) | 0 (0.0) | NaN     |
| Recurrent MI | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Recurrent angina/ischemia | 1 (3.0)       | 2 (0.5)   | 10 (1.9) | .283    |
| Stent thrombosis | 0 (0.0)       | 1 (0.3)   | 1 (0.2) | .949    |
| Free wall rupture | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Tamponade | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Moderate to severe mitral regurgitation | 0 (0.0) | 0 (0.0) | 2 (0.4) | .235    |
| Pericarditis | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Sustained VT (> 125 bpm) | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Primary VF | 0 (0.0)       | 2 (0.5)   | 0 (0.0) | .19     |
| Secondary VF | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| New atrial fibrillation | 0 (0.0)       | 5 (1.3)   | 10 (1.9) | .327    |
| High degree (2nd-3rd) AV block | 0 (0.0) | 1 (0.3) | 2 (0.4) | .664    |
| Asystole | 0 (0.0)       | 0 (0.0)   | 0 (0.0) | NaN     |
| Stroke | 0 (0.0)       | 2 (0.5)   | 4 (0.8) | .539    |
| Acute renal failure | 1 (3.0)       | 4 (1.1)   | 13 (2.5) | .282    |
| Bleeding | 0 (0.0)       | 7 (1.9)   | 7 (1.4) | .868    |
| Blood transfusions | 0 (0.0)       | 4 (1.1)   | 7 (1.4) | .512    |

**Laboratory tests**

| Peak CK (U/L) value (median [IQR]) | 217.00 (118.00, 558.00) | 218.00 (114.75, 459.75) | 156.50 (90.50, 337.75) | <.001 |
| Peak troponin I elevated | 16 (94.1) | 160 (90.9) | 200 (88.1) | .268 |
| Peak troponin T elevated | 16 (94.1) | 213 (94.7) | 318 (95.5) | .627 |
| Earliest creatinine (mg/dl) (median [IQR]) | 0.98 (0.78, 1.09) | 0.90 (0.77, 1.03) | 0.94 (0.80, 1.12) | .005 |

**Treatment at discharge**

| Aspirin | 33 (100.0) | 354 (96.5) | 496 (96.5) | .587 |
| P2Y12 | 28 (84.8) | 341 (93.2) | 461 (90.4) | .598 |
| P2Y12 type | | | | |
| Prasugrel | 9 (30.0) | 53 (14.9) | 54 (10.8) | .004 |
| Ticagrelor | 15 (50.0) | 198 (55.6) | 251 (50.4) | .249 |
| Clopidogrel | 6 (20.0) | 105 (29.5) | 193 (38.8) | .001 |
| Statins | 31 (96.9) | 359 (99.4) | 489 (98.8) | .856 |
| ACE-I/ARB | 26 (83.9) | 278 (83.7) | 385 (84.8) | .702 |
| Beta-blockers | 24 (77.4) | 266 (80.6) | 398 (84.9) | .077 |

**30-day clinical outcomes**

| Rehospitalization | 5 (17.9) | 54 (16.5) | 82 (17.0) | .932 |
| Recurrent MI | 0 (0.0) | 3 (0.9) | 2 (0.4) | .578 |
| Recurrent angina | 0 (0.0) | 5 (2.7) | 11 (3.7) | .379 |

(Continues)
guidelines are based did not necessarily examine only 24 h as a definition for early catheterization but included studies in which the definition for early intervention was longer. Another explanation might be the availability of interventional teams worldwide, which are not on-site 24/7; hence, the ability and desire to perform early coronary angiography to all NSTEMI patients admitted outside the regular working hours are not optimal. Another important possible explanation is the paradigm shift embedded in the new guidelines. In the past, there was an opposite approach of waiting several days for “cooling” of the infarct in NSTEMI patients. The idea stemmed from the fear of embolization of nonocclusive thrombus overlying the ruptured plaque, which may cause a periprocedural MI or consequent slow/no-reflow phenomenon if immediate PCI is undertaken in such lesions. Another option, and perhaps the most important one, is the tendency to postpone PCI in complicated and unstable patients such as old patients with several comorbidities (i.e., diabetes mellitus and renal failure) to allow stabilization and bring them in an optimally hemodynamic and respiratory condition for PCI. In these patients, there is, sometimes, an operator preference to postpone PCI for the morning hours when additional staff is present, in case a complication occurs during the procedure. Importantly, the fact that the study is a nationwide study also suggests that these findings do not reflect an independent practice of a single-center but rather reflect a broader conceptual attitude toward the NSTEMI guidelines.

There is ample evidence of the prognostic importance of complying with medical guidelines. Moreover, studies have shown that in NSTEMI patients, adherence to guidelines reduces mortality in the first 3 years after infarction. The fact that compliance with the guidelines is so low, even in a small country where every hospital has PCI capabilities, emphasizes the difficulty of meeting these standards, at least when it comes to PCI timing.

Our study has several limitations: First, the study is an observational study and, as such, is subjected to confounding factors. For example, there is naturally a selection bias in choosing whom to proceed with early PCI. This can be seen in the data—the high-risk NSTEMI patients with the delayed PCI were older and suffered more from comorbidities, which probably influenced the decision of the operator to delay the procedure. Second, there was no difference in the mortality rate or MACE between the various intervention groups. However, the study was not powered to demonstrate such differences. The main strengths of our study are the fact that it is based on real-world data and represents a nonselected consecutive NSTEMI patient population. Furthermore, it is based on a multicenter nationwide; therefore, the results do not reflect a single-center approach and are more generalizable.

5 | CONCLUSION

In conclusion, our data suggest that despite the recent guidelines recommendations for immediate and early PCI in very high-risk and high-risk NSTEMI patients, respectively, most patients do not undergo immediate or early PCI. Further studies are needed to better understand the reasons for guidelines’ nonadherence in those high-risk patients.

ACKNOWLEDGMENT

This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

DATA AVAILABILITY STATEMENT

Data available on request from the authors.

ORCID

Lior Lupu http://orcid.org/0000-0003-4873-2887
Katia Orvin http://orcid.org/0000-0003-2523-6469
Yacov Shacham http://orcid.org/0000-0003-0805-3185

REFERENCES

1. GBD. 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Lond Engl. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9
2. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917-938. doi:10.1016/S0025-6196(11)60509-0
3. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of
13. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/het510

14. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575

15. Lubovich A, Hamood H, Behar S, Rosenschein U. Bypassing the emergency room to reduce door-to-balloon time and improve outcomes of patients with ST elevation myocardial infarction: the Acute Coronary Syndrome Israeli Survey experience. Isr Med Assoc J IMAJ. 2011;13(4):216-219.

16. Pollack CV Jr, Holland JE, Chen AY, et al. Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA Guidelines CRUSADE initiative. Crit Pathw Cardiol. 2009;8(1):29-33. doi:10.1097/HPC.0b013e3181980f9f

17. Oosterwerff EF, Fagel ND, Slagboom T, et al. Impact of percutaneous coronary intervention timing on 5-year outcome in patients with non-ST-segment elevation acute coronary syndromes. The “wait a day” approach might be safer. Neth Heart J Mon J Neth Soc Cardiol Neth Heart Found. 2016;24(3):173-180. doi:10.1007/s12471-016-0803-0

18. Graham MM, Ghali WA, Southern DA, Traboulsi M, Knudtson ML, APPROACH Investigators. Outcomes of after-hours versus regular working hours primary percutaneous coronary intervention for acute myocardial infarction. BMJ Qual Saf. 2011;20(1):60-67. doi:10.1136/bmjqs.2010.041137

19. Farmakis IT, Zafeiropoulos S, Pagiantza A, et al. Guideline adherence is associated with long-term all-cause mortality in patients after an acute coronary syndrome. Eur Heart J. 2020;41(Suppl_2). doi:10.1093/ehjci/ehaa946.2972

20. Ricci-Cabello I, Vásquez-Mejía A, Canelo-Aybar C, et al. Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries. BMC Health Serv Res. 2020;20(1):920. doi:10.1186/s12913-020-05753-x

21. Voortman T, Kiefte-de Jong JC, Ikram MA, et al. Adherence to the 2015 Dutch dietary guidelines and risk of non-communicable diseases and mortality in the Rotterdam Study. Eur J Epidemiol. 2017;32(11):993-1005. doi:10.1007/s10654-017-0295-2

22. Shah BR, O'Brien EC, Roe MT, Chen AY, Peterson ED. The association of in-hospital guideline adherence and longitudinal post-discharge mortality in older patients with non-ST-segment elevation myocardial infarction. Am Heart J. 2015;170(2):273-280. doi:10.1016/j.ahj.2015.05.007

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Lupu L, Taha L, Banai A, et al. Immediate and early percutaneous coronary intervention in very high-risk and high-risk non-ST segment elevation myocardial infarction patients. Clin Cardiol. 2022;45:359-369. doi:10.1002/clc.23781